Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perifosine in Biochemically Recurrent Prostate Cancer
NCT00058214Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2003
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perifosine in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Prostate-Specific Antigen Response up to 6 years. Started Mar 2003; status: terminated.
02
Drugs
perifosine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00058214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058214.